STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 99 filers reported holding STOKE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,739 | -70.4% | 3,741 | -20.1% | 0.00% | -100.0% |
| Q2 2023 | $49,780 | +138177.8% | 4,683 | +9.1% | 0.00% | +100.0% |
| Q1 2023 | $36 | -88.7% | 4,293 | -87.6% | 0.00% | -92.3% |
| Q4 2022 | $319 | -99.3% | 34,493 | +914.8% | 0.01% | +1200.0% |
| Q3 2022 | $44,000 | -30.2% | 3,399 | -28.8% | 0.00% | 0.0% |
| Q2 2022 | $63,000 | -66.8% | 4,775 | -47.3% | 0.00% | -50.0% |
| Q1 2022 | $190,000 | +153.3% | 9,060 | +189.0% | 0.00% | +100.0% |
| Q4 2021 | $75,000 | +87.5% | 3,135 | +100.2% | 0.00% | 0.0% |
| Q3 2021 | $40,000 | -84.3% | 1,566 | -79.2% | 0.00% | -85.7% |
| Q2 2021 | $254,000 | +323.3% | 7,535 | +385.2% | 0.01% | +600.0% |
| Q1 2021 | $60,000 | -51.6% | 1,553 | -22.3% | 0.00% | -75.0% |
| Q4 2020 | $124,000 | -49.0% | 1,999 | -72.4% | 0.00% | +33.3% |
| Q3 2020 | $243,000 | +117.0% | 7,231 | +53.7% | 0.00% | -40.0% |
| Q2 2020 | $112,000 | – | 4,704 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |